Literature DB >> 24532559

Impact of single atrial fibrillation catheter ablation on implantable cardioverter defibrillator therapies in patients with ischaemic and non-ischaemic cardiomyopathies.

Jedrzej Kosiuk1, Sotirios Nedios2, Angeliki Darma2, Sascha Rolf2, Sergio Richter2, Arash Arya2, Christopher Piorkowski2, Thomas Gaspar2, Philipp Sommer2, Daniela Husser2, Gerhard Hindricks2, Andreas Bollmann2.   

Abstract

AIMS: Atrial fibrillation (AF) is associated with frequent appropriate and inappropriate implantable cardioverter defibrillator (ICD) therapies. Catheter ablation of AF has been shown to reduce AF burden and improve left ventricular function in heart failure patients but the impact on ICD therapies has not yet been studied. The aim of this study was to test the hypothesis that AF ablation reduces ICD therapies in patients with cardiomyopathies. METHODS AND
RESULTS: In 73 consecutive patients (mean age 59 ± 10 years, 85% male) with previously implanted ICD due to ischaemic (n = 30) or dilated cardiomyopathy (n = 43) undergoing AF ablation, the prevalence and frequency of ICD therapies before and after AF ablation were compared. During the total follow-up of 3.3 ± 3 years prior to AF ablation, 5.1 ± 14.7 therapies per patient-year were delivered as opposed to 1.8 ± 10.9 in a period of 1.1 ± 0.9 years after ablation (P = 0.002). Prior to AF ablation, 39 patients (53%) received at least one ICD therapy when compared with 15 patients (21%) after ablation. Atrial fibrillation ablation was associated with freedom from any therapy regardless of appropriateness (odds ratio, OR, 0.366, CI 0.164-0.816, P = 0.014, adjusted for follow-up). Appropriate shocks significantly decreased from 0.3 ± 1.3 to 0.1 ± 0.5 per patient-year (P = 0.030). While heart failure medication and use of antiarrhythmic drugs were comparable during the entire follow-up, a statistically significant improvement of left ventricular ejection fraction (LVEF) from 36.9 ± 12.3% to 40.7 ± 6.7% (P = 0.008) was observed after AF ablation.
CONCLUSIONS: In patients with ischaemic or dilated cardiomyopathy, catheter ablation of AF is associated with the reduction of inappropriate and appropriate ICD therapies and improvement of LVEF. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2014. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Ablation; Atrial fibrillation; ICD; Shocks

Mesh:

Year:  2014        PMID: 24532559     DOI: 10.1093/europace/euu018

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  5 in total

Review 1.  Invasive therapies for patients with concomitant heart failure and atrial fibrillation.

Authors:  Wei Wei; Michael Shehata; Xunzhang Wang; Fang Rao; Xianzhan Zhan; Huiming Guo; Xianhong Fang; Hongtao Liao; Jian Liu; Hai Deng; Yang Liu; Yumei Xue; Shulin Wu
Journal:  Heart Fail Rev       Date:  2019-09       Impact factor: 4.214

2.  Case Report: Pulmonary Vein Isolation as a Tailored Treatment for Recurrent Ventricular Tachycardia During Hemodialysis in a Patient With Right Coronary Artery Chronic Total Occlusion.

Authors:  Cosmin Cojocaru; Adelina Pupăză; Corneliu Iorgulescu; Sebastian Onciul; Lucian Câlmâc; Radu Vătăşescu
Journal:  Front Cardiovasc Med       Date:  2022-05-30

Review 3.  Ablation for Atrial Fibrillation in Heart Failure with Reduced Ejection Fraction.

Authors:  Jackson J Liang; David J Callans
Journal:  Card Fail Rev       Date:  2018-05

Review 4.  Optimal Strategies to Reduce Inappropriate Implantable Cardioverter-defibrillator Shocks.

Authors:  Blake E Fleeman; Ryan G Aleong
Journal:  J Innov Card Rhythm Manag       Date:  2019-04-15

5.  Predictors of rhythm outcomes after cardiac resynchronization therapy in atrial fibrillation patients: When should we use an atrial lead?

Authors:  Sotirios Nedios; Michael Doering; Angeliki Darma; Johannes Lucas; Borislav Dinov; Arash Arya; Nikolaos Dagres; Gerhard Hindricks; Andreas Bollmann; Sergio Richter; Kerstin Bode
Journal:  Clin Cardiol       Date:  2020-12-09       Impact factor: 2.882

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.